Torudokimab
托芦奇单抗
Report date: 2024/09/19 20:00:08
Base Information
Drug NameTorudokimab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[13]
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesZ33 Bio IncZura Bio LtdEli Lilly And Company
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A